Idera Pharmaceuticals reported $36.6M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Aceto ACET:US 192.23M 16.5M
Alnylam Pharmaceuticals ALNY:US $ 1093.99M 348.22M
Amgen AMGN:US $ 11969M 5339M
Biogen BIIB:US $ 1541.8M 200.2M
Biomarin Pharmaceutical BMRN:US $ 617.14M 24.39M
Cytrx CYTR:US 16.46M 8.02M
Dynavax Technologies DVAX:US $ 246.35M 116.74M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Gilead Sciences GILD:US $ 6837M 1944M
GlaxoSmithKline GSK:LN 3453M 50M
Idera Pharmaceuticals IDRA:US $ 36.6M 3.99M
Mirati Therapeutics MRTX:US $ 176.78M 82.21M
Nektar Therapeutics NKTR:US $ 54.02M 98.33M
Sarepta Therapeutics SRPT:US $ 1599.11M 98.16M
Seattle Genetics SGEN:US $ 685.17M 271.74M
Ultragenyx Pharmaceutical RARE:US $ 197.54M 93.34M